Ultime notizie per Bon Natural Life (NASDAQ:BON) Azioni

Bon Natural Life

Bon Natural Life Ltd is engaged in the manufacturing of personal care ingredients, such as plants extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements. Xi'an App-Chem is devoted to providing high quality and competitive prices and a stable supply of products and services for the functional food, personal care, natural medicine and other industries. It provides these products and services for third party customers, as well as for its own proprietary brands. The company has its geographic presence in PRC and in Overseas. The company derives maximum revenue from Bioactive food ingredients.

movers image

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

ZKIN

Strategie finanziarie per individuare opportunità di crescita nel settore dei materiali e ottimizzare il tuo portafoglio d&#39;investimento.

3 azioni che potrebbero rivoluzionare il tuo portafoglio questo mese

Bon Natural Life Limited - Class A Ordinary Shares

Bon Natural Life Ltd

PIMCO Active Bond Exchange-Traded Fund Exchange-Traded Fund

BarnBridge - United States Dollar

Bondly

Bone ShibaSwap

Bonk - United States Dollar

BONAL INTL INC by Bonal International, Inc.

Bonal International Inc

BON-TON STORES INC by Bon-Ton Stores, Inc. (THE)

The Bon-Ton Stores Inc

BONTERRA RES INC ORD by Bonterra Resources Inc.

BonTerra Resources Inc

Bonanza Goldfields Corp

Piper Sandler analyst David Westenberg maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Neutral and raises the price target from $260 to $280.

Price Target

Analyst Ratings

Laboratory Corporation Of America Holdings

Piper Sandler Maintains Neutral on Labcorp Hldgs, Raises Price Target to $280

<a href="https://www.eia.gov/outlooks/steo/" title="https://www.eia.gov/outlooks/steo/">https://www.eia.gov/outlooks/steo/</a>

Macro Economic Events

Econ #s

Economics

EIA Sees 2025 U.S. Natgas Output Of 104.9 BCF/Day, Vs Prior Forecast 105.3 BCF/Day; Sees 2026 Demand Of 106.4 BCF/Day; Sees 2025 U.S. Oil Demand Of 20.5M Barrels/Day, Vs Prior Forecast 20.4M Barrels/Day; Sees 2026 Demand Of 20.4M Barrels/Day; Sees 2025 U.S. Natgas Demand Of 91.3 BCF/Day, Vs Prior Forecast 91.2 BCF/Day; Sees 2026 Demand Of 90.7 BCF/Day

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $420 to $423.

VRTX

RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $423

EIA Says U.S. Oil Production To Average 13.37M Barrels/Day In May Vs 13.33M Barrels/Day In April; To Average 13.4M Barrels/Day In June; Natural Gas Production To Average 115.2 BCF/day In May Vs 115.5 BCF/Day In April; To Average 115.8 BCF/Day In June; Sees 2025 U.S. Oil Output Of 13.42M Barrels/Day, Vs Prior Forecast 13.51M Barrels/Day; Sees 2026 Output Of 13.49M Barrels/Day

Piper Sandler analyst David Westenberg maintains NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) with a Overweight and lowers the price target from $18 to $12.

Piper Sandler Maintains Overweight on NeoGenomics, Lowers Price Target to $12

Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) with a Overweight and raises the price target from $50 to $60.

Piper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $60

WIIM

CRBP

Corbus Pharmaceuticals Holdings shares are trading lower. The company reported Q1 financial results.

Scotiabank analyst Ben Isaacson maintains Albemarle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) with a Sector Perform and lowers the price target from $75 to $65.

Scotiabank Maintains Sector Perform on Albemarle, Lowers Price Target to $65

RBC Capital analyst Brad Erickson reiterates Upwork (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) with a Sector Perform and maintains $18 price target.

Reiteration

UPWK

RBC Capital Reiterates Sector Perform on Upwork, Maintains $18 Price Target

Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGT#NASDAQ">FLGT</a>) with a Neutral and raises the price target from $16 to $23.

FLGT

Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $23

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Overweight and raises the price target from $11 to $13.

ADPT

Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $13

Piper Sandler analyst Kashy Harrison maintains Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) with a Overweight and raises the price target from $286 to $360.

Piper Sandler Maintains Overweight on Quanta Services, Raises Price Target to $360

Although billionaire hedge fund manager&nbsp;Paul Tudor Jones&nbsp;believes AI can be a force for good, he also issued a stark warning on Tuesday suggesting it has the potential to <a href="https://www.benzinga.com/news/24/06/39319028/terminator-in-real-life-ai-godfather-warns-of-human-wipe-out-in-5-to-20-years">wipe out 50% of humanity</a>.
What Happened: Tuesday on CNBC&#8217;s &#8220;Squawk Box,&#8221; Jones, the founder and chief investment officer of&nbsp;Tudor Investment, warned of the negative potential of <a href="http://benzinga.com/topic/ai">AI</a> based on takeaways from a technology conference he attended two weeks ago. 
Although he acknowledged that he&#8217;s &#8220;not a tech expert,&#8221; he said the conference featured a panel of four of the &#8220;leading modelers&#8221; of the top AI models being used today, who all agreed that there is at least a small chance that AI could cause significant harm to the human race. 
There were three big takeaways from the panel, he said. First, AI can be a force for good and we are going to start seeing it in education and healthcare in the very near future. Second, these AI models are increasing their efficiency and performance by 25% to 500% every three or four quarters. Lastly, AI &#8220;clearly poses an imminent threat&#8221; to humanity, he said. 
When asked about what they were doing to prepare for the security threat that AI poses, one of the panel members said he was buying 100 acres in the Midwest and raising chickens and cattle. According to Jones, the panelist also said that the world is not likely to take the threat of AI really seriously until an &#8220;accident&#8221; occurs where &#8220;50 to 100 million people die. &#8221; He added that no one else on the panel pushed back against that idea.
&#8220;Afterwards, we had a breakout session, which was really interesting. All 40 people got up in a room like this and they had a series of propositions and you had to either agree with or disagree with the proposition,&#8221; Jones said. 
&#8220;One of the propositions was there&#8217;s a 10% chance in the next 20 years that AI will kill 50% of humanity &#8230; the vast majority of the room moved to the disagree side &#8230; all four modelers were on the agree side.&#8221;
Check This Out: <a href="https://in.benzinga.com/tech/25/05/45191784/elon-musk-wants-his-legacy-to-be-advancing-civilization-says-without-truth-seeking-ai-the-future-could-be-dangerous">Elon Musk Wants His Legacy To Be Advancing Civilization, Says Without &#8216;Truth-Seeking AI,&#8217; The Future Could Be &#8216;Dangerous&#8217;</a>
Jones told CNBC that the room then debated the proposition. One of the modelers suggested that it&#8217;s possible that someone could &#8220;bio hack&#8221; a weapon that could take out half of humanity, given how quickly the models are growing and commoditizing knowledge. 
&#8220;I don&#8217;t know, 10% seems reasonable to me,&#8221; Jones said. 
He emphasized that he&#8217;s not an expert in technology, but noted that he&#8217;s spent his entire life managing risk.
&#8220;We just have to realize, to their credit, all these folks in AI are telling us we&#8217;re creating something that&#8217;s really dangerous — it&#8217;s going to be really great too — but we&#8217;re helpless to do anything about it. That&#8217;s, to their credit, what they&#8217;re telling us, and yet we&#8217;re doing nothing right now and it&#8217;s really disturbing,&#8221; Jones said. 
Jones told CNBC that there was about $250 billion dollars spent on AI development among the <a href="https://www.benzinga.com/content/45185180/magnificent-7-stocks-send-a-dire-warning-to-markets">Magnificent Seven</a> tech giants in 2024. According to the four modelers at the tech conference, the AI spend on security was less than $1 billion, he said. 
To mitigate the potential downside of AI, the leading AI companies need to dramatically increase spending on AI security and President Donald Trump has to increase regulations on AI development, Jones said. 
&#8220;I just want to say one last thing. I&#8217;m really concerned about these open-source models and how they are commoditizing and making what were previously indecipherable pockets of knowledge easily accessible,&#8221; he said. 
&#8220;You can have a bad actor like Osama bin Laden take these things with his cult following somewhere down the road, or you can have innocent actors like hopefully those researchers in Wuhan laboratory make a mistake, who made a mistake, and they can be real threats to humanity.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/05/45184304/palo-alto-networks-acquires-protect-ai-for-500m-a-startup-backed-by-salesforce-samsung-and-01-advisors-in-ai-security-push">Palo Alto Networks Acquires Protect AI For $500M+, A Startup Backed By Salesforce, Samsung, And 01 Advisors In AI Security Push</a></li>
</ul>
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45045318/crowdstrike-launches-new-ai-tools-to-strengthen-cybersecurity-expand-threat-detection">CrowdStrike Launches New AI Tools To Strengthen Cybersecurity, Expand Threat Detection</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Tech

Paul Tudor Jones Warns AI Could 'Kill 50% Of Humanity' Without Proper Oversight: 'We're Creating Something That's Really Dangerous'

Scotiabank analyst Greg Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and lowers the price target from $450 to $442.

Scotiabank Maintains Sector Perform on Vertex Pharmaceuticals, Lowers Price Target to $442

Piper Sandler analyst Kashy Harrison maintains Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) with a Overweight and lowers the price target from $30 to $21.

AMRC

Piper Sandler Maintains Overweight on Ameresco, Lowers Price Target to $21

Affordable staples now available for delivery from more than 5,000 Family Dollar locations coast to coast
Today, Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) announced the launch of a new partnership with Family Dollar, one of America's most trusted discount retailers, bringing its broad selection of affordable household items to Uber Eats. With more than 5,000 Family Dollar locations now live on Uber Eats across the U.S., customers can shop for a wide variety of everyday items—from cleaning supplies and pantry staples to beauty products and baby care—delivered directly to their door, on-demand or scheduled.

UBER

Uber Technologies Announces The Launch Of A New Partnership With Family Dollar, Bringing Its Broad Selection Of Affordable Household Items To Uber Eats

RBC Capital analyst Matthew Hedberg maintains ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) with a Outperform and raises the price target from $1060 to $1100.

RBC Capital Maintains Outperform on ServiceNow, Raises Price Target to $1100

Piper Sandler analyst Korinne Wolfmeyer reiterates Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) with a Neutral and raises the price target from $35 to $39.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Piper Sandler Reiterates Neutral on Hims & Hers Health, Raises Price Target to $39

CF Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFBK#NASDAQ">CFBK</a>) reported quarterly earnings of $0.68 per share. This is a 44.68 percent increase over earnings of $0.47 per share from the same period last year. The company reported $14.12 million in sales this quarter. This is a 15.80 percent increase over sales of $12.19 million the same period last year.

Earnings

CFBK

CF Bankshares Q1 EPS $0.68 Up From $0.47 YoY, Sales $14.12M Up From $12.19M YoY

TruBridge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBRG#NASDAQ">TBRG</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-05-07. Here's what investors need to know before the announcement.
Analysts estimate that TruBridge will report an earnings per share (EPS) of $0.29. 
The market awaits TruBridge's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.34, leading to a 7.49% increase in the share price on the subsequent day.
Here's a look at TruBridge's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.39</td>
<td>0.27</td>
<td>0.17</td>
<td>0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.05</td>
<td>-0.21</td>
<td>0.16</td>
<td>0.19</td>
</tr>
<tr>
<td>Price Change %</td>
<td>7.000000000000001%</td>
<td>-0.0%</td>
<td>24.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746547423_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of TruBridge were trading at $26.29 as of May 05. Over the last 52-week period, shares are up 211.12%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Opinions on TruBridge</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on TruBridge.
Analysts have given TruBridge a total of 3 ratings, with the consensus rating being Neutral. The average one-year price target is $28.33, indicating a potential 7.76% upside.
<h3>Comparing Ratings with Competitors</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Claritev, Definitive Healthcare and Health Catalyst, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Claritev, with an average 1-year price target of $19.0, suggesting a potential 27.73% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Definitive Healthcare, with an average 1-year price target of $3.0, suggesting a potential 88.59% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Health Catalyst, with an average 1-year price target of $5.81, suggesting a potential 77.9% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary outlines pivotal metrics for Claritev, Definitive Healthcare and Health Catalyst, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>TruBridge</td>
<td>Neutral</td>
<td>10.26%</td>
<td>$49.78M</td>
<td>-1.72%</td>
</tr>
<tr>
<td>Claritev</td>
<td>Neutral</td>
<td>-4.91%</td>
<td>$175.01M</td>
<td>-94.63%</td>
</tr>
<tr>
<td>Definitive Healthcare</td>
<td>Neutral</td>
<td>-5.53%</td>
<td>$47.60M</td>
<td>-12.43%</td>
</tr>
<tr>
<td>Health Catalyst</td>
<td>Neutral</td>
<td>6.02%</td>
<td>$34.69M</td>
<td>-5.74%</td>
</tr>
</tbody>
</table>

Key Takeaway:
TruBridge ranks at the bottom for Revenue Growth and Gross Profit, while it ranks in the middle for Return on Equity.
<h3>Unveiling the Story Behind TruBridge</h3>
TruBridge Inc is a provider of healthcare solutions and services for community hospitals, clinics, and other healthcare systems. It provides services such as Electronic health records &amp; information systems, revenue cycle management, population health, and data management, etc. The segments of the company are Revenue Cycle Management (RCM), (ii) Electronic Health Records (EHR), and (iii) Patient Engagement The company derives maximum revenue from the RCM segment.
<h3>TruBridge: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: TruBridge displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 10.26%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: TruBridge's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -3.23%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): TruBridge's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -1.72%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): TruBridge's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.74% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.04.
<a href="https://www.benzinga.com/quote/TBRG/earnings">To track all earnings releases for TruBridge visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Bon Natural Life

Notizie

Ultime notizie per Bon Natural Life (NASDAQ:BON) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO